Triamcinolone
Find information on thousands of medical conditions and prescription drugs.

Triamcinolone hexacetonide

Triamcinolone (trade names Kenalog®, Aristocort®, Nasacort®, Tri-Nasal®) is a synthetic corticosteroid given orally, by injection, inhalation, or as a topical cream. An injection is used in many situations where a lasting corticosteroid effect is required. This includes replacement therapy in people whose adrenal glands are not producing enough natural steroids (adrenal insufficiency) and decreasing inflammation in certain disease states. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Corticosteroids such as triamcinolone decrease inflammation by acting within cells to prevent the release of certain chemicals that are important in the immune system. These chemicals are normally involved in producing immune and allergic responses, resulting in inflammation. By decreasing the release of these chemicals in a particular area, inflammation is reduced. This can help control a wide number of disease states, characterised by excessive inflammation. They include severe allergic reactions, inflammation of the lungs in asthma and inflammation of the joints in arthritis. The injection can be given as a single dose to people who suffer from hayfever and do not respond to conventional therapy. This can relieve symptoms over the entire hayfever period. Triamcinolone may also be given by injection directly into a joint to relieve inflammation and pain and increase mobility of the affected joint, in conditions such as arthritis.

Triamcinolone also decreases the numbers of white blood cells circulating in the blood. This is useful for the treatment of certain types of leukaemia, where there is an abnormally large production of certain white blood cells. It is also used to treat some autoimmune diseases, which are caused by the immune system attacking the body's own tissues.

Triamcinolone is used in much higher doses than the levels of corticosteroids produced naturally by the body, and as such, the usual actions of corticosteroids become exaggerated and can be observed as side effects of this medicine.

Different triamcinolone salts are available, including acetonide, hexacetonide and diacetate.

Read more at Wikipedia.org


[List your site here Free!]


Do steroid injections help with osteoarthritis of the knee?
From Journal of Family Practice, 11/1/04 by Luis C. Palacios

* EVIDENCE-BASED ANSWER

Intra-articular steroid injections appear to provide 2 to 6 weeks of pain relief for patients with knee osteoarthritis (strength of recommendation [SOR]: A). Higher-dose steroids with or without joint lavage can provide pain relief up to 24 weeks (SOR: A). Steroid injections may be an appropriate adjunct in the treatment of osteoarthritis, which includes nonpharmacologic treatments (education, weight loss, physical therapy) and pharmacologic therapy (nonsteroidal anti-inflammatory drugs [NSAIDs], topical and opioid analgesics). (1,2)

* EVIDENCE SUMMARY

Osteoarthritis, also known as degenerative joint disease, is the most prevalent form of arthritis in the United States. (3) For the elderly, it is a common cause of pain and disability, affecting patients' ability to perform activities of daily living. Common causes of osteoarthritis include past and present biomechanical stresses affecting the articular cartilage, sub-chondral bone changes, and biochemical changes in the articular cartilage and synovial membrane. (3)

Treatment of patients with osteoarthritis of the knee should be individualized to the severity of symptoms for each patient. A treatment plan can include patient education, physical and occupational therapy, non-opioid oral and topical agents, NSAIDs, intra-articular corticosteroid injections, viscosupplementation injections, arthroscopic lavage, and total knee replacements.

Our knowledge of the long-term safety and efficacy of intra-articular knee corticosteroid injection is based on limited data. In a randomized, double-blind, placebo-controlled crossover study, investigators randomized 59 patients aged 51 to 89 years to receive either an intra-articular injection of 1 mL of 40 mg methylprednisolone or 1 mL of 0.9% saline. After 3 weeks, patients receiving steroid injection had a minimal change in baseline visual analogue score for pain compared with those receiving saline (median change: -2.0 mm vs 0 mm on a 100-ram scale). (4)

A randomized, single-blinded study involving 84 patients demonstrated significant self-reported "overall improvement" for patients given intra-articular triamcinolone hexacetonide (78%) compared with placebo (49%) after 1 week (P<.05). (5) It also confirmed reports that visual analogue score for pain and distance walked in 1 minute improves significantly for both steroid- and placebo-treated groups up to 6 weeks. Only the steroid-treated patients exhibited improved walking distance at 1 week compared with baseline (P<.001).

A recent randomized, double-blind, placebo-controlled trial studied the long-term safety and efficacy of treatment of knee osteoarthritis with repeated steroid injections. (6) These investigators studied 66 patients aged 40 to 80 years recruited from rheumatology clinics. One half (n=33) received injections of triamcinolone acetonide 40 mg, and the other half received saline injections every 3 months for 2 years. At 1- and 2-year interval follow-ups, no statistically significant difference was seen between the 2 groups in loss of joint space and no progression of degenerative disease, as demonstrated by measurements of joint space widths by standardized fluoroscopically guided radiographs. Although the primary outcome measure of this study was to assess radiologic joint space narrowing with repeated injections, knee pain and stiffness appeared to improve after 2 years, although these results were not well quantified.

A limitation of most studies testing intra-articular therapy has been sample size. Combining studies may allow the ability to detect levels of pain relief not found in individual studies. A recent meta-analysis of 6 randomized controlled trials using intra-articular corticosteroid knee injections found short-term relief of pain for 2 weeks (relative risk [RR]=1.66; 95% confidence interval [CI], 1.37-2.01). (7) The number needed to treat (NNT) range for these studies is 1.3 to 3.5. Two additional studies included in this study using higher-dose steroids (prednisone equivalent dose of 37.5 to 80 mg), with or without joint lavage, assessed improvement at 16 to 24 weeks. Although neither individual study showed statistically significant differences, the pooled data from the 2 studies favored symptom improvement at 16 to 24 weeks (RR=2.09; 95% CI, 1.2-3.7; NNT=4.4). (7)

* RECOMMENDATIONS FROM OTHERS

Guidelines for the treatment of knee osteoarthritis were outlined by a task force for the European League Against Rheumatism (EULAR) Standing Committee for Clinical Trials. The task force recommended intra-articular steroid injection for acute exacerbation of knee pain. This task force performed an evidence-based review and concluded at least 1 randomized control trial recommended intra-articular steroid for patients with osteoarthritis. It was noted that intra-articular steroid injections were effective for only short-term pain relief and that there are no predictors of success of treatment, such as the presence or absence of such factors as joint effusion, degree of radiologic change, age, or obesity. (2)

The American College of Rheumatology Subcommittee on Osteoarthritis Guidelines developed both nonpharmacological and pharmacological recommendations for the treatment of osteoarthritis of the knee. (8) These recommendations include: use of intra-articular steroid injection for patients with acute exacerbations who had evidence for joint inflammation, and joint aspiration accompanying the intra-articular injection for "short-term relief."

Luis C. Palacios, MD, Wanwisa Y. Jones, MD, Helen G. Mayo, MLS, University of Texas Southwestern, Dallas

REFERENCES

(1.) Rozental TD, Sculco TP. Intra-articular corticosteroids: an updated overview. Am J Orthop 2000; 29:18-23.

(2.) Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000; 59:936-944.

(3.) Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995; 38:1541-1546.

(4.) Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. Ann Rheum Dis 1996; 55:829-832.

(5.) Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis 1995; 54:379-381.

(6.) Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48: 370-377.

(7.) Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. BMJ 2004; 328: 869-870.

(8.) Altman RD, Hochberg HC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee 2000 update: American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43:1905-1915.

* CLINICAL COMMENTARY

Intra-articular steroids provide extra relief for patients with acute exacerbations

This well-constructed review demonstrates that intra-articular steroid injections provide up to 3 weeks of pain relief for patients with osteoarthritis of the knee. While this may not seem like much, in practice it can be quite helpful in some situations. It provides supplemental pain relief for patients with acute exacerbations of their disease. It is also useful as a temporizing measure for patients who are candidates for total knee replacement but are not quite ready for it psychologically.

Wail Malaty, MD, Hendersonville Family Practice Residency Program, Hendersonville, NC

COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Triamcinolone hexacetonide
Home Contact Resources Exchange Links ebay